|
| |
Lorus TherapeuticsLorus Therapeutics Inc. is a pharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer.
The Company is currently developing a number of novel anti-cancer compounds called NuChem Analogues, based on a commonly used anti-fungal agent, clotrimazole. This technology includes the anti-cancer applications of clotrimazole itself. Clotrimazole has been shown to have unique anti-proliferative activities against cancer cells, including the inhibition of key steps in tumour growth and angiogenesis (new blood vessel formation). Preclinical investigation of a number of these compounds in different tumour models is currently underway.
Virulizin®, a sterile liquid drug formulation for injection, is also being developed. Virulizin® is a new drug with novel biological response modifier activities. It has been shown to stimulate normal peripheral blood monocytes to express cytocidal activity in a dose-dependent manner. North American clinical investigations have focused on advanced pancreatic cancer, malignant melanoma, invasive cervicaluterine carcinoma and HIV-related Kaposi's sarcoma.
Lorus Therapeutics' objective is to maximize the therapeutic value and potential commercial success of its technology. The Company intends to pursue specific developmental, manufacturing, marketing and distribution arrangements with one or more strategic pharmaceutical partners. No such arrangements have been finalized, but the Company is in late-stage discussions with potential strategic partners.
To expand its product pipeline, Lorus Therapeutics is currently reviewing in-licensing opportunities involving new products and technologies in the areas of oncology. Lorus is focusing its efforts on developing therapies with different targets to provide tools for the management of the disease. By treating patients using drugs from several different therapeutic areas, using each drug alone or in combination, the chances of successfully managing cancer can be increased significantly. Lorus is currently developing cytostatic and immunotherapy drug candidates and will continue to look for products in different areas.
| Contact Details: |
| 2 Meridian Road |
| Toronto |
| Ontario |
| M9W 4Z7 |
| Canada |
| Tel: | 416-798-1200 |
| Fax: | 416-798-2200 |
| Email: | info@lorusthera.com |
| WWW: | www.lorusthera.com/
|
|
Loading...
|
Recent Publications by Lorus Therapeutics: |  |
A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis.
ML-133 is a novel small molecule with potent antiproliferative activity,... | 17th September, 2009
| Lorus Therapeutics Inc., Toronto, Ontario M9W 4Z7 Canada.
| Mol Cancer Ther. 2009 Sep;8(9):2586-96. Epub 2009 Sep 15.
DOI Direct Link |
GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
GTI-2040, an antisense oligonucleotide targeting the small subunit of... | 25th February, 2009
| Lorus Therapeutics Inc., Toronto, Ontario M9W 4Z7, Canada.
| Int J Oncol. 2009 Jan;34(1):33-42.
|
Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
Virulizin has demonstrated strong antitumor efficacy in a variety of human... | 17th December, 2008
| Research and Development Department, Lorus Therapeutics Inc., 2 Meridian
| Cancer Immunol Immunother. 2008 Dec;57(12):1757-69. Epub 2008 Mar 20.
DOI Direct Link |
Global comparative analysis of ESTs from the southern cattle tick, Rhipicephalus (Boophilus) microplus.
BACKGROUND: The southern cattle tick, Rhipicephalus (Boophilus) microplus,... | 16th January, 2008
| Lorus Therapeutics Inc; 2 Meridian Road, Toronto, ON M9W 4Z7, Canada.
| BMC Genomics. 2007 Oct 12;8:368.
DOI Direct Link |
Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
Virulizin, a novel biological response modifier, has demonstrated broad... | 31st October, 2007
| Research and Development Department, Lorus Therapeutics Inc., 2 Meridian
| Int Immunopharmacol. 2007 Oct;7(10):1350-9. Epub 2007 Jun 26.
DOI Direct Link |
→View more Lorus Therapeutics research publications. |
Press Releases on Lorus Therapeutics:
|
 |
| /C O R R E C T I O N from Source -- Lorus Therapeutics Inc./ |
21st July, 2008 |
Lorus Therapeutics Inc. |
TORONTO, July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (Lorus),
a biopharmaceutical company specializing in the research and development of
pharmaceutical products and technologies for
|
| Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 |
21st July, 2008 |
Lorus Therapeutics Inc. |
TORONTO, July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the
|
| Lorus Therapeutics Receives $600 Thousand From Escrow Account |
16th July, 2008 |
Lorus Therapeutics Inc. |
TORONTO, July 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and
|
| Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) |
2nd July, 2008 |
Lorus Therapeutics Inc. |
TORONTO, July 2 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:
LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company
specializing in the research
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1384 times since April 2007, the link to the organisation's website has been followed 181 times Recent Search Terms used to find this page: Lorus Therapeutics Toronto | ML-133 | ML-133 | ML-133 | Lorus Therapeutics LOR-2040 chance of success | virulizin 2009 | ML-133 Lorus | ML-133 and Lorus | lorus therapeutics | Lorus Therapeutics | . Search for more companies in Toronto Search for more companies in Ontario This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Lorus Therapeutics |
